The eucaryotic cell cycle is regulated by the periodic synthesis and destruction of cyclins that associate with and activate cyclin-dependent kinases. Cyclindependent kinase inhibitors, such as p21 and p16, also play important roles in cell cycle control by coordinating internal and external signals and impeding proliferation at several key checkpoints. Understanding how these proteins interact to regulate the cell cycle has become increasingly important to researchers and clinicians with the discovery that many of the genes that encode cell cycle regulatory activities are targets for alterations that underlie the development of cancer. Several therapeutic agents, such as DNA-damaging drugs, microtubule inhibitors, antimetabolites, and topoisomerase inhibitors, take advantage of this disruption in normal cell cycle regulation to target checkpoint controls and ultimately induce growth arrest or apoptosis of neoplastic cells. Other therapeutic drugs being developed, such as UCN-01, specifically inhibit cell cycle regulatory proteins.
INTRODUCTION
The eucaryotic cell cycle is divided into four stages: G1, S, G2, and M. G1 is the gap phase during which cells prepare for the process of DNA replication. It is during the G1 phase that the cell integrates mitogenic and growth inhibitory signals and makes the decision to proceed, pause, or exit the cell cycle. An important checkpoint in G1 has been identified in both yeast and mammalian cells. Referred to as start in yeast and the restriction point in mammalian cells, this is the point at which the cell becomes committed to DNA replication and completing a cell cycle (1-3). S phase is defined as the stage in which DNA synthesis occurs. G2 is the second gap phase during which the cell prepares for 295 0362-1642/99/0415-0295$08.00 the process of division. M stands for mitosis, the phase in which the replicated chromosomes are segregated into separate nuclei and cytokinesis occurs to form two daughter cells. In addition to G1, S, G2, and M, the term G0 is used to describe cells that have exited the cell cycle and become quiescent.
Much of what is known about the regulated transition of cells through the cell cycle comes from genetic and biochemical studies carried out in lower organisms. One of the first genes to be identified as being an important regulator of the cell cycle in yeast is cdc2/cdc28 (4, 5). Activation of the cdc2/cdc28 kinase requires association with a regulatory subunit referred to as a cyclin. Cyclins were first identified in marine invertebrates as proteins whose accumulation and degradation oscillated during the cell cycle (6). It is the sequential activation and inactivation of cyclin-dependent kinases (cdks), through the periodic synthesis and destruction of cyclins, which provide the primary means of cell cycle regulation.
In contrast to only the one or two cdc2/cdc28-like gene products found in lower eucaryotes, nine cdks (referred to as cdk1-9) have been identified in mammalian cells. In addition, at least 16 mammalian cyclins have been identified: A, B1, B2, C, D1, D2, D3, E, F, G1, G2, H, I, K, T1, and T2 (Table 1) . All cyclins contain a common region of homology known as the cyclin box, which is a domain used to bind and activate cdks. Not all cyclins and cdks function in regulating the cell cycle, however. Other functions identified for cyclins and cdks include regulation of transcription, DNA repair, differentiation, and apoptosis. For example, several cyclin/cdk complexes, including cyclin C/cdk8, cyclin T/cdk9, and cyclin H/cdk7, have been found to be components of the basal transcription machinery (7-9). Each of these cyclin/cdk complexes has been implicated in regulating transcriptional elongation through phosphorylation of the carboxy-terminal domain (CTD) of the largest subunit of RNA polymerase II. A newly isolated mammalian cyclin, cyclin K, is found to be in complex with RNA polymerase II and, through the activation of an unidentified cdk, can also promote CTD phosphorylation (10). In addition to cyclin binding, other levels of regulation also exist for controlling cdk activity during the cell cycle. Phosphorylation of cdk subunits can both positively and negatively regulate kinase activity (11) . It is now becoming clear that ubiquitin-mediated proteolysis plays a crucial role in cell cycle control by targeting cyclins and other regulators for destruction at key times during the cell cycle (12, 13) . The irreversibility of proteolysis provides a strong directionality to the cell cycle, forcing it to go forward at several critical steps. Association with two families of proteins, the cdk inhibitors (CKI), is also an important level of cdk regulation. Interestingly, some CKIs appear to positively regulate the cell cycle by functioning as assembly factors for cyclin D/cdk complexes (14) . The expanding roles of the CKIs in cell cycle control are discussed below.
PROGRESSION FROM G0 THROUGH THE CELL CYCLE
The D-type cyclins are the first cyclins to be induced as G0 cells are stimulated to enter the cell cycle (15) . Unlike many other cyclins, D-type cyclins do not oscillate during the cell cycle, but rather their levels are controlled by the presence of growth factors. D-type cyclins associate with and activate cdk4 and cdk6. Studies from knockout mice demonstrate that cyclin D1, D2, and D3 are, for the most part, functionally redundant but that each has unique tissuespecific functions (16) . The primary substrate for D-type cyclin kinases is the retinoblastoma tumor suppressor protein (Rb). In cells lacking Rb, D-type cyclin kinase activity is not required for cell cycle progression (17) . In addition to functioning as regulatory subunits for cdk4 and cdk6, D-type cyclins also help to target Rb and Rb-related proteins for phosphorylation through direct protein-protein interaction (18) (19) (20) .
The Rb protein plays a critical role in regulating G1 progression and is likely a key component of the molecular network controlling the restriction point. Rb has been shown to bind and regulate a large number of cellular proteins, including members of the E2F family of transcription factors (Figure 1 ) (21) . E2F factors regulate the expression of many genes that encode proteins involved in cell cycle progression and DNA synthesis, including cyclins E and A, cdc2 (cdk1), B-myb, dihydrofolate reductase, thymidine kinase, and DNA polymerase α. Binding of Rb to E2F inhibits E2F's transcriptional activation capacity and, in at least some cases, converts E2F factors from transcriptional activators to transcriptional repressors. Phosphorylation of Rb by D-type cyclin kinases results in the dissociation of Rb from E2F and the expression of the above mentioned E2F-regulated genes.
Through the activation of E2F, cyclin E is the next cyclin to be induced during the progression of cells through G1 (22, 23) . Cyclin E associates with cdk2, and this kinase complex is required for cells to make the transition from G1 into S phase (24) . Cyclin E/cdk2 participates in maintaining Rb in the hyperphosphorylated state (25) and thus participates in a positive feedback loop for the accumulation of active E2F. Unlike the D-type cyclins, however, cyclin E kinase activity is still required in cells lacking Rb, suggesting that there are additional critical substrates for cyclin E/cdk2 (24) . Like many other cyclin/cdk complexes, cyclin E/cdk2 phosphorylates histone H1, and this activity may be important for the chromatin rearrangement required during the replication of the genome.
Cyclin A, which is also regulated in part by E2F (26) , accumulates at the G1/S phase transition and persists through S phase. Cyclin A initially associates with cdk2 and then, in late S phase, associates with cdk1. Cyclin A-associated kinase activity is required for entry into S phase, completion of S phase, and entry into M phase (27) (28) (29) . Cyclin A colocalizes with sites of DNA replication, suggesting that cyclin A may actively participate in DNA synthesis or perhaps play a role in preventing excess DNA replication. At least some members of the E2F family are negatively regulated by cyclin A. E2F1, E2F2, and E2F3 contain domains that directly bind cyclin A. This allows cyclin A-associated kinases to phosphorylate the E2F heterodimerization partner DP1, resulting in an inhibition of E2F DNA-binding activity. Thus, whereas cyclin E positively regulates E2F activity, cyclin A participates in a negative feedback loop for E2F regulation.
The G2 phase also contains a checkpoint that responds to DNA damage and causes a delay to allow DNA repair before the cell enters into mitosis. Mitosis is regulated by cdk1 in association with cyclins A, B1, and B2 (11, 30) . The proteins these cyclin/cdk1 complexes phosphorylate include cytoskeleton proteins such as lamins, histone H1, and possibly components of the mitotic spindle. For cells to exit mitosis, cyclins A and B must be degraded, and experiments suggest that cyclin B/cdk1 kinases participate in the regulation of this destruction process. After mitosis, cells again enter G1 and, at the restriction point, must decide whether to proceed into another cell cycle.
CYCLIN-DEPENDENT KINASE INHIBITORS

Cip/Kip Family
Two families of CKI exist. Members of the Cip/Kip family can act on most cyclin/cdk complexes and even on some kinases unrelated to cdks. The first of this family to be isolated was p21
Cip1/WAF1/SDI1/CAP20/PIC1/mda-6 (p21) (31) . The large number of aliases reflects the different strategies used to identify and clone p21 and illustrates the multifunctional nature of this protein. Several labs isolated p21 through its ability to interact with cdk2, although it can interact with cyclin complexes containing other cdks as well. In addition, p21 can also interact with PCNA, an elongation factor for DNA polymerase δ, as well as a component of the DNA repair machinery (32) . The binding of p21 inhibits the ability of PCNA to function in DNA replication but not DNA repair.
The p21 gene was also cloned as a gene induced by the p53 tumor suppressor protein (33) . In response to DNA damage, the p53 protein is stabilized and activated as a transcription factor. The p21 gene promoter contains a p53-binding site that allows p53 to transcriptionally activate the p21 gene. Induction of p21 inhibits cell cycle progression in two ways: (a) by inhibiting a variety of cyclin/cdk complexes and (b) by inhibiting DNA synthesis through PCNA binding. Cells that lack p21 are deficient in their ability to arrest in G1 in response to DNA damage (34) . Thus p21 appears to be the critical mediator of p53's response to DNA damage through its ability to inhibit cell proliferation but allow DNA repair. p21 was also isolated as a gene that accumulated as aged cells approached senescence, suggesting that p21 may play a role in this cellular process as well (35) .
The other two members of the Cip/Kip family are p27 Kip1 (p27) and p57
Kip2
(p57). Like p21, p27 and p57 bind to a variety of cyclin/cdk complexes through a conserved amino-terminal domain (36) (37) (38) . p27 has been implicated in mediating several growth inhibitory signals including transforming growth factor-β (TGF-β) and contact inhibition (36) . Mice lacking p27 are abnormally large, have multiple organ hyperplasia, and are predisposed to developing pituitary tumors (39-41). In contrast to the ubiquitous expression of p21 and p27, p57 displays a tissue-specific expression pattern suggesting a specialized role in cell cycle control. Interestingly, the p57 gene locus is subject to imprinting, with preferential expression of the maternal allele, and is linked to several cancer syndromes. Although not considered part of the Cip/Kip family, two Rb-related proteins, p107 and p130, contain domains with homology to the amino terminus of Cip/Kip proteins (42). Like Cip/Kip proteins, p107 and p130 can bind at least some cyclin/cdk complexes, namely cyclin A/cdk2 and cyclin E/cdk2, and inhibit their kinase activity (43).
There is some controversy as to the stoichiometry of Cip/Kip proteins to cyclin/cdk proteins and the effect this has on kinase activity. Studies suggest that two p21 molecules are required to inhibit one cyclin/cdk complex (44, 45). However, the cocrystal structure of p27 bound to cyclin A/cdk2 suggests that only one inhibitor molecule is sufficient for inhibition (46). Adding to this controversy is the discovery that p21, p27, and p57 can each function as assembly factors for cyclin D/cdk4 complexes (14) . At low concentrations, Cip/Kip proteins promote cdk4 kinase activity through the stabilization cyclin D/cdk4 complexes. At higher concentrations of these CKIs, however, cdk4 activity is inhibited. These findings are consistent with immunodepletion experiments that demonstrate that most cellular cyclin D and cdk4-associated kinase activity is associated with p21 (45). Moreover, studies also suggest that Cip/Kip proteins can promote nuclear localization of cyclin D/cdk4 complexes (14) . In light of these new findings, the simple model in which Cip/Kip proteins function solely as inhibitors of the cell cycle needs to be revised. p16 appears to play a unique role in regulating the status of Rb. In many cells lacking Rb, p16 is up-regulated because of a feedback loop in which Rb represses p16 gene expression (48, 49). Over expression of p16 in Rb-deficient cells has no effect on proliferation, however, consistent with the finding that D-type cyclin-associated kinase activity is not required in cells lacking Rb (50, 51). Like Rb, the p16 gene is altered in a high percentage of human tumors (52). p16 can be inactivated by a variety of mechanisms including deletion, point mutation, and silencing by hypermethylation (53-55). Interestingly, in tumors with p16 inactivated, Rb is always wild type, whereas in tumors bearing Rb mutations, p16 is wild type (53, 54). This suggests that p16 and Rb act as a single functional unit in tumor suppression. Confirmation that p16 is a tumor suppressor is complicated by the fact that the p16 gene locus encodes a second protein in an overlapping reading frame (56). This protein, p19 ARF , has recently been shown to regulate p53 protein stability (57, 58).
INK4 Family
In many tumors and cell lines with p16 deletion, the related and closely linked p15 gene is also affected (59, 60). Despite the close homology and linkage, p16 and p15 appear to have very different biological roles. The level of p15 is unaffected by Rb status but is induced by the growth-inhibitory cytokine TGF-β (61). After TGF-β treatment, newly synthesized p15 binds to cdk4 and cdk6. This results in a displacement of p27 from cdk4 and cdk6 complexes and the accumulation of p27 in cyclin E/cdk2 complexes (62) . Thus, INK4 proteins can regulate the activity of other cdks through this indirect displacement mechanism. p18 and p19 may also be responsive to extracellular stimuli. Treatment of Daudi cells with the inhibitory cytokine interferon α altered the pattern of p18 expression (63) . Furthermore, interleukin-6 induces both p18 and p19 levels in hematopoietic cells, and this correlates with G1 arrest and terminal differentiation (64) .
ALTERED CELL CYCLE CONTROL IN CANCER
Several genes encoding regulatory activities that govern the cell cycle, particularly the progression of quiescent cells through G1 and into S phase, are targets for genetic and epigenetic alterations that underlie the development of many human neoplasias (59, 60). The best characterized of these is cyclin D1, also known as Prad1 because it was cloned as a gene involved in a translocation in parathyroid adenomas (65) . It is also now clear that cyclin D1 is the Bcl1 oncogene, the gene involved in the t(11;14) (q13;q32) translocation associated with certain B-cell lymphomas. Cyclin D1 gene amplification also occurs in a subset of breast, esophageal, bladder, lung, and squamous cell carcinomas. In addition, cyclin D1 is over expressed in some primary tumors and tumor cell lines that lack obvious cyclin D1 gene rearrangement, perhaps through a mechanism that increases cyclin D1 protein stability. In several animal model systems, deregulated expression of cyclin D1 has been shown to directly contribute to tumorigenesis (66) (67) (68) .
Cyclins D2 and D3 have also been reported to be over expressed in some tumors (59, 69). In addition, the catalytic partners of D-type cyclins, cdk4 and cdk6, are over expressed in some tumors and tumor cell lines. Moreover, mutant cdk4 and cdk6 proteins that are resistant to negative regulation by INK4 inhibitors but retain kinase activity have been isolated from human tumors (70, 71) . INK4 family members can be inactivated by mutation, deletion, or methylation in human tumors (72) . The p16 gene locus appears to be second only to p53 in its involvement in human cancers. A familial melanoma syndrome is associated with an inactivating mutation in the p16 gene, and many sporadic tumors have inactivated p16. p15 deletions are found in many of the sporadic tumors with p16 deletion and, in a small subset of tumors, p15 may be inactivated without involvement of p16 (72) . Finally, the p18 gene is located in a region that is often abnormal in breast tumors, and a p18 mutant defective in binding cdk6 has been isolated from a breast cancer cell line (73) .
It is assumed that over expression of D-type cyclins, cdk4 and cdk6, or inactivation of INK4 inhibitors results in the functional inactivation of Rb. As mentioned, hyperphosphorylated Rb is unable to bind and negatively regulate E2F transcription factors. Consistent with this model is the finding that ectopic expression of D-type cyclins in quiescent cells stimulates the expression of at least some E2F-regulated genes (74, 75) . Although alterations in E2F genes have yet to be identified in human cancers, there is strong circumstantial evidence that points to the deregulation of E2F transcriptional control as being a key event in tumorigenesis. Several E2F genes have been shown to function as oncogenes in cell culture-based transformation assays (76) (77) (78) (79) . Moreover, deregulated expression of E2F1 in a transgenic mouse model has recently been shown to contribute to the development of skin tumors in cooperation with either an activated ras gene or p53 deficiency (80, 81) .
Alterations in other cell cycle regulators have also been implicated in human cancer. Cyclin E has been found to be amplified, over expressed, or both in some breast, colon, and leukemic cancers (69, 82 ). An oncogenic potential for cyclin E has been demonstrated experimentally in both cell culture assays and transgenic mice (83, 84) . A single instance in which cyclin A was altered in a human hepatoma has been reported (85) . The p57 gene is located at a chromosomal site that is rearranged in some sporadic tumors and may be associated with two familial cancer syndromes, Wilms tumor (WT2) and Beckwith-Wiedmann syndrome (37, 38). However, other candidate genes exist in this region of the genome, and there is, as yet, no definitive evidence that p57 is the critical target for cancer development.
Although very few alterations in p21 are found in human cancers (72, 86) , it is implicated in tumorigenesis through its regulation by the p53 tumor suppressor protein. The p53 gene is the most frequently mutated gene in human cancer. An important role for p53 is as a cell cycle checkpoint regulator (72, 86) . p53 stabilization in response to DNA damage results in either a G1 or G2 phase arrest, which may allow DNA repair to occur. In cells lacking p53, genome stability is compromised leading to increased mutations, amplifications, and chromosomal abnormalities. There is strong evidence to suggest that p21 is the key mediator of the ability of p53 to regulate these cell cycle checkpoints (34) . However, p21-deficient mice do not develop spontaneous tumors as do p53-deficient mice, suggesting that p21 is not a major mediator of the tumor suppressor function of p53. The ability of p53 to induce apoptosis, which is independent of p21, may be the critical activity of p53 in tumor suppression. On the other hand, p21-deficient keratinocytes do have increased proliferative potential and are transformed by a ras oncogene, whereas wild-type or p27-deficient keratinocytes are not transformed by ras (87) . This suggests that p21-mediated checkpoint control does function to inhibit oncogenic transformation in some cell types.
THERAPEUTIC TARGETS
Modulation of the Cell Cycle
The disruption of normal cell cycle regulation, which is the hallmark of cancer, presents numerous opportunities for targeting checkpoint controls to develop new therapeutic strategies for this disease. Such strategies include induction of checkpoint arrest leading to cytostasis and ultimately apoptosis, arrest of proliferating cells in stages of the cell cycle which may sensitize them to treatment with other therapeutic agents such as radiation, and targeting of therapies toward specific regulatory components of the cell cycle.
As illustrated in Figure 2 , chemotherapeutic agents intervene at multiple points in the cell cycle. These drugs have diverse mechanisms of action and exhibit specificity in terms of the stage of the cell cycle in which they have activity. In Table 2 , several classes of chemotherapeutic agents and their mechanisms of action are listed along with information regarding their effects on the cell cycle.
One of the most established chemotherapeutic approaches is the induction of DNA damage and subsequent induction of apoptosis. Agents such as cisplatin and nitrogen mustard, which induce DNA cross-links and chromosome breakage, can cause cell cycle arrest at both the G1/S and G2/M checkpoints (88) (89) (90) (Figure 2 ). G1 arrest is mediated by p53, which induces an increase in p21, resulting in inhibition of cyclin/cdk2 and cyclin/cdk4 complexes and hypophosphorylation of Rb (90-91a) . Up-regulation of p21 also results in sequestration of PCNA, which contributes to arrest at G1/S. The G2/M checkpoint induced by DNA damage can occur by either p53-dependent or -independent mechanisms (91b, 91c). Both p21 and phosphorylation of cdk1 is required for entry into M and can participate in the DNA damage G2/M checkpoint. Tumor cells in which p53 is inactive can bypass the G1/S checkpoint and exhibit increased sensitivity to DNA-damaging agents such as cisplatin (92) as a result of failure to arrest and repair their damaged DNA.
Microtubule inhibitors such as taxol and vinca alkyloids disrupt normal tubulin polymerization/depolymerization and mitotic spindle formation (93, 94) . As a result, cells either initiate a p53-dependent arrest at the mitotic spindle assembly checkpoint (94a), a radiosensitive phase of the cell cycle, or continue to progress through M and become aneuploid and arrest in G1 (91c, 94b-97) . Arrest in G2/M produced by these drugs is associated with stabilization of cyclin B/cdc2 complexes (97a). Tumor cells treated with microtubule inhibitors can undergo apoptosis from both G1 and G2 arrest (98) . Microtubule inhibitors have also proven effective in the clinic as radiosensitizers. Combined chemotherapy/radiotherapy with taxol, which blocks cells at the mitotic spindle assembly checkpoint, can enhance the sensitivity of radiation-resistant tumors to radiotherapy (99, 100) . Depletion of ribonucleotide pools by nucleoside analogs such as hydroxyurea and gemcitibine can also activate the G1 checkpoint arrest at a point that may be distinct from that associated with DNA damage (101, 102) . This second G1 checkpoint is mediated by p53 and also requires up-regulation of p21 (102) . In checkpoint-defective cells, such as those with inactive p53, bypass of the G1/S checkpoint produces DNA strand breaks, resulting in cell death (102a). Both gemcitibine and hydroxyurea have also been effectively used as radiosensitizers for a variety of tumor types (103) . Antimetabolites such as methotrexate and 5-fluorouracil inhibit thymidylate synthase and DNA synthesis and induce a p53-dependent S-phase arrest (104-104b) . In tumor cells in which p53 is inactive, DNA damage induced by these drugs goes undetected, and cells progress to G2 and subsequently undergo apoptosis (89, 90) . These drugs are also used clinically as radiosensitizers as a result of their ability to arrest cells in the radiosensitive phase of the cell cycle (104b).
Topoisomerase inhibitors also cause DNA damage, resulting in increased levels of cyclin A and S-phase arrest or inactivation of cylin B/cdk2 complexes and G2/M arrest (104c-104e). In addition to the prominent role of p53/p21-mediated activity for many of the above-named drugs, the activity of topoisomerase inhibitors can also be mediated by the Rb/p16 pathway. In some cell types, drugs such as camptothecin and etoposide produce an increase in p16, which inhibits phosphorylation of Rb resulting in a G1 cell cycle arrest (105, 106) . Therefore, in addition to p53, their activity may also be dependent on the presence of a functional Rb protein. Tumor cells that lack functional Rb can bypass this checkpoint and progress through the cell cycle, becoming genetically unstable and acquiring additional genetic alterations including changes in ploidy.
Direct Inactivation of Checkpoint Controls
Some successful or potentially successful therapeutic strategies involve the use of agents that target cell cycle regulatory molecules. As mentioned previously, the activity of cyclin-kinase complexes is regulated by phosphorylation, and several cdk inhibitors have been identified which exhibit specificity for the ATP-binding pocket of these cdks (107) and block their phosphorylation. Chemical inhibitors of cdks such as olomoucine and its analog roscovitine exhibit specificity for cdk1 and cdk2 (108, 109) . These inhibitors can induce both G1 and G2 arrest as well as apoptosis (107) . As mentioned above, in response to DNA-damaging agents, some tumor cells can arrest in G2 in a p53-independent manner. This G2/M checkpoint arrest occurs as a result of phosphorylation and inactivation of cdk1. Staurosporine and its second-generation analog 7-hydroxystaurosporine (UCN-01) inhibit the phosphorylation of cdk1, resulting in the activation of this M-phase regulator and abrogating the G2/M arrest (110, 110a). Use of UCN-01 has been most successful in combination with DNA-damaging agents such as cisplatin (111) and camptothecin (104c) in p53-deficient cells that can bypass the G1 checkpoint and would otherwise arrest in G2. As a consequence of UCN-01 treatment, tumor cells that have sustained DNA damage progress through the cell cycle beyond the G2/M checkpoint and undergo apoptosis (112) (Figure 2 ). Similar strategies with several agents (such as caffeine) that abrogate the G2 checkpoint by activating cdk1 have been shown to preferentially sensitize p53-deficient cells to other genotoxic agents such as radiation and etoposide (113) (114) (115) .
Active cyclin D-kinase complexes, which serve to phosphorylate Rb and release E2F, can also be inhibited by small peptides derived from p16 (116) . A 20-amino-acid peptide of p16 can bind cdk4, inhibit activation of cyclin D-cdk4 activity, and block cell cycle progression through G1. As predicted, this cell cycle arrest requires a functional Rb protein (116) . Similarly, double-stranded DNA with high affinity for E2F can act as a molecular decoy, compete for E2F binding to DNA, and inhibit the ability of E2F to regulate target genes such as cdc2 (cdk1) and cyclin E (117, 118) .
Summary
In summary, an understanding of the cell cycle targets of different chemotherapeutic agents has prognostic implications and can have significant consequences for the development of resistance of tumors to chemotherapy and tumor evolution. Identification of the status of p53 and Rb in tumors before therapy can be incorporated into selection of chemotherapeutic agents, for instance by establishing the presence of wild-type p53 or Rb in tumors before the administration of drugs that target specific pathways in which these genes function. Conversely, the absence of an appropriate checkpoint response in tumors may, under some circumstances, permit damaged cells to progress through the cell cycle without an appropriate arrest to repair this damage, resulting in cell death. The presence of mutant or inactive p53 or Rb and increased expression of genes such as p21 in tumors can contribute to resistance to chemotherapy, which is often observed with drugs such as cisplatin. Another caveat is that treatment with drugs that induce genetic alterations or aneuploidy or that are clastogenic can accelerate tumor progression in those cases in which tumors lack the required checkpoint controls to undergo arrest or apoptosis in response to chemotherapy with these drugs. Such progression can lead to selection of more malignant tumor phenotypes and an associated adverse disease outcome.
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